Literature DB >> 25090003

Hypersensitivities to non-steroidal anti-inflammatory drugs.

Ahmad A Mourad1, Sami L Bahna.   

Abstract

NSAIDs are the most commonly used medications worldwide and are responsible for almost 25% of adverse drug reactions. Such reactions can have different manifestations and can be immunologic or non-immunologic. The diagnosis is primarily based on the medical history, which can be difficult in patients receiving multiple medications. Because skin testing and blood tests are not valid for NSAIDs reactions, confirmation requires an appropriately-designed challenge. The latter could be avoided when the history is obvious and the reaction is life-threatening. The challenge route can be oral, nasal, or bronchial. Avoidance of the causative NSAID, often associated with the avoidance of the cross-reacting preparations, is the cornerstone of management. In most cases, a safe substitute can be used. When treatment with the causative NSAID is necessary, titrated desensitization can be performed. This review discusses the classes of NSAIDs, mechanisms of their adverse reactions, manifestations, diagnosis, and management.

Entities:  

Keywords:  NSAIDs; aspirin challenge; aspirin desensitization; aspirin exacerbated respiratory disease; cyclooxygenase; drug adverse reaction; drug hypersensitivity

Mesh:

Substances:

Year:  2014        PMID: 25090003     DOI: 10.1586/1744666X.2014.946905

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

1.  Remove orthopedic fracture implant with minimal invasive surgery is good for the patient's early rehabilitation.

Authors:  Tiannan Zou; Qiaohong Li; Xiaoxiao Zhou; Zhao Yang; Ge Wang; Wei Liu; Chao Zhang
Journal:  Int J Clin Exp Med       Date:  2015-12-15

2.  Aspirin-Induced Delayed Urticaria in Children with Kawasaki Disease: A Retrospective Case-Control Study.

Authors:  Yao Lin; Yaqi Li; Jingjing Ma; Aijie Li; Yang Liu; Lin Shi
Journal:  Int J Gen Med       Date:  2021-11-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.